دورية أكاديمية
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry.
| العنوان: | Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry. |
|---|---|
| المؤلفون: | Ballas L; Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: Leslie.Ballas@cshs.org., Ailawadhi S; Department of Hematology, Mayo Clinic, Jacksonville, Florida., Narang M; US Oncology Research, Maryland Oncology Hematology, Columbia, Maryland., Gasparetto CJ; Department of Medicine, Duke University Medical Center, Durham, North Carolina., Lee HC; The Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hardin JW; Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, South Carolina., Durie BGM; Department of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California., Toomey K; Department of Internal Medicine, Medical Oncology, and Hematology, Steeplechase Cancer Center, Somerville, New Jersy., Omel J; Myeloma Research Advocate/Advisor, Grand Island, Nebraska., Wagner LI; Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina., Abonour R; Department of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana., Terebelo HR; Department of Hematology, Internal Medicine, and Medical Oncology, Providence Cancer Institute, Southfield, Michigan., Joshi P; Bristol Myers Squibb, Princeton, New Jersey., Yu E; Bristol Myers Squibb, Princeton, New Jersey., Liu L; Bristol Myers Squibb, Princeton, New Jersey., Rifkin RM; Department of Medical Oncology/Hematology, Rocky Mountain Cancer Centers, US Oncology, Denver, Colorado., Jagannath S; Department of Hematology and Medical Oncology, Mount Sinai Hospital, New York, New York. |
| المصدر: | Practical radiation oncology [Pract Radiat Oncol] 2024 Mar-Apr; Vol. 14 (2), pp. e141-e149. Date of Electronic Publication: 2023 Nov 19. |
| نوع المنشور: | Observational Study; Multicenter Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101558279 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-8519 (Electronic) Linking ISSN: 18798500 NLM ISO Abbreviation: Pract Radiat Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York : Elsevier |
| مواضيع طبية MeSH: | Multiple Myeloma*/radiotherapy , Osteoporosis*, Adult ; Humans ; Prospective Studies ; Ethnicity ; Registries |
| مستخلص: | Purpose: Radiation therapy (RT) is an important treatment modality for patients with multiple myeloma (MM). Although patients are living longer with MM, they are more likely to have comorbidities related to treatment, such as bone pain; however, RT can provide symptom relief. To date, the characterization of patients who have received RT in the real-world setting has been limited. Methods and Materials: The Connect® MM Registry is a large, US multicenter, prospective observational cohort study of adult patients with newly diagnosed MM from mostly community sites. RT utilization and outcomes were analyzed quarterly throughout treatment. Factors associated with RT use were identified via multivariable analysis. Results: A total of 3011 patients were enrolled in the Connect MM Registry with 903 patients (30%) having received RT at any time. There was a significant difference (P < .05) in overall RT use among patients with an Eastern Cooperative Oncology Group performance status of 0 to 1 versus ≥2, International Staging System disease stage I/II versus III, a history of plasmacytoma or a novel agent in their first regimen, and any number of bone lesions or severe osteoporosis/fracture. RT use was associated with having bone lesions or severe osteoporosis (vs not having bone lesions). Additionally, RT use was associated with ethnicity (Hispanic vs not) and Connect MM Registry cohort (cohort 1 [enrolled 2009-2011] vs 2 [enrolled 2012-2016]). In the 6 months before death, increased RT use was associated with increasing number of treatment lines (P < .0001) and high- versus standard-risk disease (per International Myeloma Working Group criteria; P = .0028). Conclusions: Real-world results from the Connect MM Registry show RT is frequently used and is associated with clinical factors, including performance status and disease stage. Earlier in MM diagnosis, RT may be used as an adjunct to palliate symptoms or delay systemic therapy. Toward the end of life, RT is more frequently used for palliation when treatment options are often limited. Competing Interests: Disclosures Dr Ballas reports travel fees associated with a leadership role with the American Board of Radiology and fees for providing expert legal testimony. Dr Ailawadhi reports consulting fees from GSK, Sanofi, Bristol Myers Squibb (BMS), Takeda, BeiGene, Janssen, Regeneron, Cellectar, and Pfizer; serving on a scientific steering committee for BMS; and research funding for his institution from GSK, BMS, Pharmacyclics, Amgen, Janssen, Cellectar, AbbVie, Ascentage, and Sanofi. Dr Gasparetto reports payments or honoraria, and travel fees from Sanofi, Karyopharm, and BMS; serving on a scientific steering committee for BMS; and serving on advisory boards for Pfizer, Janssen, and BMS. Dr Lee reports grants or contracts from Amgen, BMS, Janssen, GSK, Regeneron, and Takeda; consulting fees from BMS, Celgene, Genentech, Janssen, Regeneron, GSK, Sanofi, Pfizer, Monte Rosa Therapeutics, Takeda, and Allogene Therapeutics; and serving on a scientific steering committee for BMS. Dr Rifkin is a current employee of McKesson and reports serving on data safety monitoring boards for CARsgen; advisory boards for Amgen, BMS, Coherus, Fresenius Kabi, Genmab, and Janssen; and a scientific steering committee for BMS. Dr Jagannath reports consultancy fees from BMS, Janssen, Legend Biotech, Regeneron, Takeda, Sanofi, and Karyopharm; serving on steering committees and data safety monitoring or advisory boards for Janssen, BMS, and Sanofi; support for attending IMS, ASH, and ASCO; and leadership or fiduciary roles with IMS, SOHO, and ASH. Dr Narang, James W. Hardin, Brian G. M. Durie, Kathleen Toomey, James Omel, Lynne Wagner, Rafat Abonour, Howard R. Terebelo report serving on a scientific steering committee for BMS. Dr Joshi, Edward Yu, and Liang Liu are employees of BMS. (Copyright © 2023 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.) |
| تواريخ الأحداث: | Date Created: 20231120 Date Completed: 20240304 Latest Revision: 20240304 |
| رمز التحديث: | 20240304 |
| DOI: | 10.1016/j.prro.2023.11.004 |
| PMID: | 37984714 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1879-8519 |
|---|---|
| DOI: | 10.1016/j.prro.2023.11.004 |